4.7664

0.29% +0.0139

Polypid Ltd (PYPD)

Overview News Price History Discussions Forecast Stock Split

Polypid Ltd stock is currently priced at $4.7664, with a 24-hour trading volume of 2,267. It has seen a +0.29% increased in the last 24 hours and a +3.62% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $4.80 pivot point. If it approaches the $4.70 support level, significant changes may occur.

Previous Close:

$4.7525

Open:

$4.7249

24h Volume:

2,267

Market Cap:

$22.99M

Revenue:

Net Income/Loss:

$-23.87M

P/E Ratio:

-0.1313

EPS:

-36.3

Net Cash Flow:

$-47.63M

1W Performance:

+7.72%

1M Performance:

+3.62%

6M Performance:

+26.10%

1Y Performance:

+1,035%

1D Range:

$4.63

$4.793

52W Range:

$0.2006

$9.20

Polypid Ltd Stock (PYPD) Company Profile

Name

Polypid Ltd

Sector

Healthcare (1203)

Industry

Biotechnology (688)

Phone

972 7 4719 5700

Address

18 Hasivim Street, PO Box 7126, Petah Tikva

Employee

Twitter

Next Earnings Date

2024-05-08

Latest SEC Filings

PYPD's Discussions on Twitter

Polypid Ltd Stock (PYPD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-14-21	Initiated	JMP Securities	Mkt Outperform
Jul-30-21	Initiated	Cantor Fitzgerald	Overweight
Nov-24-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-10-20	Initiated	Alliance Global Partners	Buy
Jul-21-20	Initiated	BMO Capital Markets	Outperform
Jul-21-20	Initiated	Barclays	Overweight
Jul-21-20	Initiated	Raymond James	Outperform

View All

Polypid Ltd Stock (PYPD) Latest News

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

GlobeNewswire Inc.

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

GlobeNewswire Inc.

PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc.

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

GlobeNewswire Inc.

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

GlobeNewswire Inc.

Polypid Ltd Stock (PYPD) Financials Data

Polypid Ltd (PYPD) Net Income 2024

PYPD net income (TTM) was -$23.86 million for the quarter ending December 31, 2023, a +39.67% increase year-over-year.

Polypid Ltd (PYPD) Cash Flow 2024

PYPD recorded a free cash flow (TTM) of -$47.63 million for the quarter ending June 30, 2023.

Polypid Ltd (PYPD) Earnings per Share 2024

PYPD earnings per share (TTM) was -$19.67 for the quarter ending December 31, 2023, a +67.75% growth year-over-year.

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.